JP2022535452A5 - - Google Patents

Info

Publication number
JP2022535452A5
JP2022535452A5 JP2021572559A JP2021572559A JP2022535452A5 JP 2022535452 A5 JP2022535452 A5 JP 2022535452A5 JP 2021572559 A JP2021572559 A JP 2021572559A JP 2021572559 A JP2021572559 A JP 2021572559A JP 2022535452 A5 JP2022535452 A5 JP 2022535452A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036495 external-priority patent/WO2020247873A1/en
Publication of JP2022535452A publication Critical patent/JP2022535452A/ja
Publication of JP2022535452A5 publication Critical patent/JP2022535452A5/ja
Pending legal-status Critical Current

Links

JP2021572559A 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用 Pending JP2022535452A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858932P 2019-06-07 2019-06-07
US62/858,932 2019-06-07
US201962888384P 2019-08-16 2019-08-16
US62/888,384 2019-08-16
PCT/US2020/036495 WO2020247873A1 (en) 2019-06-07 2020-06-05 Antigen-binding protein constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2022535452A JP2022535452A (ja) 2022-08-08
JP2022535452A5 true JP2022535452A5 (https=) 2023-06-13

Family

ID=71899864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572559A Pending JP2022535452A (ja) 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用

Country Status (9)

Country Link
US (1) US20220313845A1 (https=)
EP (1) EP3980129A1 (https=)
JP (1) JP2022535452A (https=)
CN (1) CN114746115A (https=)
AU (1) AU2020289477A1 (https=)
CA (1) CA3142884A1 (https=)
IL (1) IL288685A (https=)
MX (1) MX2021015095A (https=)
WO (1) WO2020247873A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
US20230107901A1 (en) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Ｄｌｌ３抗原結合構築物
WO2024012524A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
TW202602935A (zh) 2024-04-01 2026-01-16 美商米西克治療公司 抗原結合蛋白構築體及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
BR112014020826A8 (pt) * 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.

Similar Documents

Publication Publication Date Title
JP2022535452A5 (https=)
Wang et al. Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment
JP6817492B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
Boado et al. Fusion antibody for alzheimer's disease with bidirectional transport across the Blood− Brain barrier and Aβ fibril disaggregation
Kubetzko et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
WO2020253568A1 (zh) 抗cd73抗体及其应用
JP2022543771A5 (https=)
CN115960230A (zh) 靶向分子的抗原结合构建体
KR20190031299A (ko) 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
CN106573983B (zh) 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段
Kwon et al. 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents
US20200255536A1 (en) Target for b-cell disorders
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2022553922A5 (https=)
JP2023544143A5 (https=)
RU2013134983A (ru) Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области
JP2021529776A5 (https=)
JP2021506817A5 (https=)
CN113512117B (zh) 一种可结合cd206的抗体及其应用
JP2022534808A5 (https=)
CZ20013270A3 (cs) Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob
JP2023103439A (ja) 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤
JP2025181917A5 (https=)
AR129303A1 (es) Anticuerpos monoclonales dirigidos contra la proteína de muerte celular programada 1 y su uso medicinal